Outset Medical (NasdaqGS:OM) FY Conference September 10, 2025 07:00 AM ET Speaker1Good morning, everyone. I'm Stephen Traynor, a Vice President with Morgan Stanley. I'm happy to be hosting Outset Medical today. With us is Leslie Trigg, CEO, and Renee Gaeta, CFO. Before we dive in, I just want to note for important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales repres ...

Core Viewpoint - Osisko Metals has reported significant new drilling results from the Gaspé Copper Project, highlighting the longest continuous mineralization intercept to date of 1117.5 meters averaging 0.25% Cu, 1.81 g/t Ag, and 0.022% Mo, which indicates strong potential for resource expansion and upgrade in mineral resource categories [1][2][9]. Summary by Relevant Sections Drilling Results - Drill hole 30-1097 achieved the longest intersection of 1117.5 meters with an average of 0.25% Cu, 1.81 g/t Ag, and 0.022% Mo, including a deeper expansion of 426.0 meters averaging 0.27% Cu [2][9]. - A total of over 65,000 meters of drilling has been completed with 10 drills on site, and the current drilling program will continue until December 2025 [2][4]. Mineral Resource Estimate (MRE) - The updated MRE is expected to be released in Q1 2026, focusing on upgrading inferred mineral resources to measured or indicated categories [2][4][17]. - The current drill program aims to convert the November 2024 MRE to Measured and Indicated categories and test for deeper and lateral expansions [17]. Mineralization Characteristics - The Gaspé Copper mineralization is characterized as porphyry copper/skarn type, with significant occurrences of chalcopyrite, pyrite, and molybdenite [15]. - High molybdenum grades (up to 0.5% Mo) have been noted in specific zones away from Copper Mountain [15]. Company Background - Osisko Metals is focused on the Gaspé Copper Project, which hosts the largest undeveloped copper resource in eastern North America, with current Indicated Mineral Resources of 824 million tonnes averaging 0.34% CuEq and Inferred Mineral Resources of 670 million tonnes averaging 0.38% CuEq [25][26]. - The company acquired a 100% interest in the Gaspé Copper mine from Glencore Canada Corporation in July 2023 [25].

Core Insights - Northwest Kidney Centers collaborates with Outset Medical to enhance access to home hemodialysis through the integration of the Tablo Hemodialysis System [1][2][3] - The partnership aims to improve patient independence and quality of life by providing an intuitive and user-friendly dialysis solution [2][3][4] Company Overview - Northwest Kidney Centers is a nonprofit organization established in 1962, recognized as the first outpatient dialysis provider and currently the eighth-largest in the U.S., serving over 2,000 patients annually [5][6] - Outset Medical is a medical technology company focused on transforming the dialysis experience, with the Tablo system being FDA-cleared for use from hospital to home [7][8] Product Features - The Tablo Hemodialysis System operates using standard tap water and electricity, simplifying the dialysis process and eliminating the need for complex infrastructure [2][3] - It features a touchscreen interface, automated setup, and cloud connectivity, making it accessible for both patients and healthcare providers [2][8] Impact on Patient Care - The collaboration is expected to empower patients by providing a more sustainable and easier-to-learn dialysis option, aligning with modern lifestyles [3][4] - Patients who participated in the pilot phase reported increased engagement and confidence in their treatment due to the system's intuitive design [2][3]

Core Viewpoint - Osisko Metals Incorporated is uplisting to the Toronto Stock Exchange (TSX) from the TSX Venture Exchange (TSXV), effective August 22, 2025, which is expected to enhance the company's visibility and access to a broader investor base [1][3][4]. Company Overview - Osisko Metals is a Canadian exploration and development company focused on critical metals, particularly copper and zinc [5]. - The company acquired a 100% interest in the Gaspé Copper mine from Glencore Canada Corporation in July 2023, which is located in Québec's Gaspé Peninsula [5]. - The Gaspé Copper project has current Indicated Mineral Resources of 824 million tonnes (Mt) grading 0.34% CuEq and Inferred Mineral Resources of 670 Mt grading 0.38% CuEq [5]. - The Gaspé Copper mine hosts the largest undeveloped copper resource in eastern North America [5]. Project Details - In addition to the Gaspé Copper project, the company is advancing the Pine Point project, one of Canada's largest past-producing zinc mining camps, through a joint venture with Appian Capital Advisory LLP [6]. - The Pine Point project has current Indicated Mineral Resources of 49.5 Mt at 5.52% ZnEq and Inferred Mineral Resources of 8.3 Mt at 5.64% ZnEq [6].

Company Overview - Outset Medical, Inc. is a medical technology company focused on transforming the dialysis experience with innovative technology [3] - The company has developed the Tablo Hemodialysis System, which is FDA-cleared for use in various healthcare settings, from hospitals to home [3] - Tablo integrates water purification and on-demand dialysate production into a single system, enhancing operational efficiency and patient care [3] Market Presence - The Tablo system is trusted by over 1,000 healthcare facilities in the U.S. and has facilitated millions of treatments administered by thousands of nurses [3] - Outset Medical aims to empower healthcare providers to establish in-house dialysis programs, leading to improved operational, clinical, and financial outcomes [3] Upcoming Events - Management will present at the 23rd annual Morgan Stanley Global Healthcare Conference on September 10, 2025, at 7 a.m. Eastern time [1] - A live and archived webcast of the presentation will be available on the company's investor relations website [2]

Group 1 - Outset Medical, Inc. (OM) has experienced a significant downtrend, with a stock decline of 26.8% over the past four weeks, but it is now in oversold territory, indicating a potential turnaround [1] - The Relative Strength Index (RSI) for OM is at 29.65, suggesting that the heavy selling pressure may be exhausting itself, which could lead to a trend reversal [5] - Analysts have raised earnings estimates for OM, with a 33.3% increase in the consensus EPS estimate over the last 30 days, indicating a potential for price appreciation [7] Group 2 - OM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [8]

Core Viewpoint - Osisko Metals has announced promising new drill results from the Gaspé Copper Project, indicating significant resource expansion potential and the possibility of increasing the mineral resource estimate (MRE) in the upcoming update scheduled for Q1 2026 [1][2][19]. Summary by Relevant Sections Drill Results - New analytical results include 20 mineralized intercepts from 7 new drill holes, with infill intercepts aimed at upgrading inferred mineral resources and expansion intercepts potentially leading to additional resources [3][5]. - Drill hole 30-0872 returned 92.1 metres averaging 0.24% Cu and 3.05 g/t Ag, followed by a higher grade intercept of 47.2 metres averaging 1.14% Cu and 11.8 g/t Ag, extending mineralization to a vertical depth of 390 metres [9][10]. - Drill hole 30-1085 intersected 219.0 metres averaging 0.41% Cu and 2.79 g/t Ag, and a second intercept of 754.5 metres averaging 0.24% Cu, extending mineralization to a vertical depth of 1110 metres [10][12]. - Drill hole 30-1092 returned 331.5 metres averaging 0.37% Cu and 3.21 g/t Ag, located 230 metres south of the 2024 MRE model [11]. - Drill hole 30-1096 intersected 730.7 metres averaging 0.29% Cu, extending mineralization to a vertical depth of 1062 metres [13]. - Drill hole 30-1099 showed 614.7 metres averaging 0.23% Cu, extending mineralization in the porphyry core of the deposit to a vertical depth of 1000 metres [15]. Resource Expansion Plans - The current drill program aims to convert the November 2024 MRE to Measured and Indicated categories and test the expansion of the system deeper and laterally [19]. - Additional drill holes are planned in the resource expansion target area, covering a surface of 450 metres by 550 metres, which is expected to add significant new tonnage to the MRE update [2][19]. Company Background - Osisko Metals is focused on the Gaspé Copper project, which hosts the largest undeveloped copper resource in eastern North America, with current Indicated Mineral Resources of 824 million tonnes averaging 0.34% CuEq and Inferred Mineral Resources of 670 million tonnes averaging 0.38% CuEq [29][30].

Core Insights - The health care sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1] - The Relative Strength Index (RSI) is a key indicator used to identify oversold conditions, with a value below 30 indicating potential buying opportunities [1] Company Summaries - **Exact Sciences Corp (EXAS)**: Reported strong quarterly results with a focus on earlier detection. Despite positive performance, the stock fell approximately 21% over the past month, with an RSI of 22.9 and a closing price of $40.99 [8] - **Tandem Diabetes Care Inc (TNDM)**: Announced mixed second-quarter results and narrowed FY25 sales guidance below estimates. The stock declined around 27% in the last five days, with an RSI of 22.7 and a closing price of $11.23 [8] - **Outset Medical Inc (OM)**: Reported better-than-expected second-quarter results and raised FY25 sales guidance. The stock fell about 34% over the past month, with an RSI of 29.6 and a closing price of $12.80 [8]

Financial Performance - Outset Medical reported a quarterly loss of $0.84 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.76, and an improvement from a loss of $7.05 per share a year ago, representing an earnings surprise of +52.27% [1] - The company posted revenues of $31.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.54% and up from $27.39 million in the same quarter last year [2] Stock Performance - Outset Medical shares have declined approximately 15.3% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for Outset Medical is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$1.61 on revenues of $30.4 million, and for the current fiscal year, it is -$5.99 on revenues of $121.7 million [7] - The estimate revisions trend for Outset Medical was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical Info Systems industry, to which Outset Medical belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Data and Key Metrics Changes - Revenue for the second quarter reached $31.4 million, representing a 15% increase compared to the previous year, driven by strong Tableau console sales and consistent utilization [6][20] - Recurring revenue from consumables and services was $22.5 million, an 11% increase year-over-year [6][21] - Non-GAAP gross margin expanded to 38.4%, up more than one percentage point from last year [7][22] - Non-GAAP operating loss was $13.4 million, a 36% reduction from the prior year [24] - Net loss for the quarter was $18.5 million, down 46% from the previous year [24] Business Line Data and Key Metrics Changes - Product revenue was $23.1 million, with console revenue at $8.9 million and consumable revenue at $14.2 million, marking a 20% increase from the prior year [21] - Consumable revenue saw a 17% increase, contributing to the overall growth in recurring revenue [6] Market Data and Key Metrics Changes - Tableau is now utilized in over 900 acute and subacute sites across the United States, indicating strong market penetration [8] - A new enterprise agreement was secured with one of the largest national health systems, potentially placing hundreds of Tableau consoles [8] Company Strategy and Development Direction - The company aims to grow console revenue, expand gross margin, and drive towards profitability, with a focus on insourcing dialysis services [17][18] - The commercial organization has undergone significant transformation, enhancing sales processes and team capabilities to better target enterprise-level opportunities [11][72] - The company is optimistic about the market opportunity, particularly in the acute care sector, where penetration remains low [56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the pipeline and market demand, despite monitoring potential impacts from federal funding cuts in healthcare [13] - The company is on track to achieve cash flow breakeven and profitability, with a goal to use less than $50 million in cash for the year [15][28] Other Important Information - The company has produced over 1.5 million Tableau disposable treatments since bringing production in-house in 2023, which is crucial for quality and cost reduction [14] - The Chief Nursing Officer's role will focus on facilitating the transition from outsourcing to insourcing dialysis services, emphasizing the importance of nursing leadership in the sales process [50] Q&A Session Summary Question: Guidance and momentum for the second half of the year - Management acknowledged strong performance in the first half and expressed optimism for the second half, citing improvements in commercial transformation and high console utilization [32][36] Question: Status of Salesforce transition and productivity - Management confirmed that the commercial organization has significantly improved, with new tools and processes enhancing sales effectiveness [39][40] Question: Sustainability of deal strength and ASPs - Management indicated that strong ASPs are supported by high uptake of new products and a diversified pipeline, with enterprise agreements expected to drive future growth [45][48] Question: Focus of the new Chief Nursing Officer - The Chief Nursing Officer will work closely with the sales organization to facilitate the transition to insourcing, leveraging her experience to guide potential customers [50] Question: Outlook for cash burn into 2026 - Management provided limited guidance but indicated that cash burn may increase as production ramps up, with more detailed guidance expected later in the year [75]